Skip to main content

Table 1 Clinical characteristics of patients with and without CMB

From: Cerebral microbleeds: prevalence and relationship to clinical features in cognitive impairment with lewy body disease

Characteristics

Without CMBs

(n = 731)

CMBs

(n = 198)

Z/\(\:{\varvec{x}}^{2}\)

P - value

Age at last visit, yrs

69.00 (64.00, 76.00)

71.50 (66.00, 77.00)

-2.922

0.003

Sex

  

16.361

< 0.001

 Men

332 (45.42%)

122 (61.62%)

  

 Women

399 (54.58%)

76 (38.38%)

  

Education, yrs

9.00 (6.00, 12.00)

9.00 (6.00, 12.00)

-0.159

0.874

Course of disease, yrs

2.00 (1.00, 3.00)

3.00 (2.00, 4.00)

-1.811

0.070

Hypertension

201 (27.50%)

95 (47.98%)

30.109

< 0.001

T2DM

64 (8.76%)

60 (30.30%)

62.545

< 0.001

Heart disease

63 (8.62%)

67 (33.84%)

82.338

< 0.001

Stroke

78 (10.67%)

57 (28.79%)

41.176

< 0.001

Smoking

75 (10.26%)

88 (44.44%)

125.846

< 0.001

Alcohol consumption

61 (8.34%)

65 (32.83%)

79.664

< 0.001

Fazekas

1.00 (1.00, 1.00)

1.00 (1.00, 2.00)

-5.860

< 0.001

MTA-left

1.00 (1.00, 1.00)

1.00 (1.00, 2.00)

-4.206

< 0.001

MTA-right

1.00 (1.00, 1.00)

1.00 (1.00, 2.00)

-4.385

< 0.001

MTA-max

1.00 (1.00, 2.00)

1.00 (1.00, 2.00)

-4.125

< 0.001

Clinical core features

n = 731

n = 198

  

 Visual hallucinations

500 (68.40%)

145 (73.23%)

1.714

0.190

 Fluctuating cognition

353 (48.29%)

119 (60.10%)

8.696

0.003

 Parkinsonism

560 (76.61%)

150 (75.76%)

0.062

0.803

 RBD

415 (56.77%)

111 (56.06%)

0.032

0.858

Motor function

n = 469

n = 128

  

 UPDRS-III

7.00 (0.00, 24.00)

10.50 (0.00, 23.75)

-0.038

0.970

 Hoehn-Yahn stage

1.00 (0.00, 2.00)

1.25 (0.00, 2.00)

-0.146

0.884

 0.0

170 (36.25%)

48 (37.5%)

4.371

0.730

 1.0

80 (17.06%)

16 (12.50%)

 1.5

38 (8.10%)

11 (8.59%)

 2.0

95 (20.26%)

30 (23.44%)

 2.5

16 (3.41%)

2 (1.56%)

 3.0

51 (10.87%)

18 (14.06%)

 4.0

15 (3.20%)

3 (2.34%)

 5.0

4 (0.85%)

0 (0.00%)

Cognitive function

n = 731

n = 198

 MMSE

20.00 (14.00, 24.00)

17.00 (13.00, 23.00)

-2.492

0.013

 MoCA

13.00 (8.00, 18.00)

12.00 (7.00, 17.00)

-2.520

0.012

 ADL

25.00 (21.00, 34.00)

29.00 (22.00, 38.00)

-2.959

0.003

 CDR

1.00 (1.00, 2.00)

2.00 (1.00, 2.00)

-2.384

0.017

Behavioral and psychological symptoms

n = 347

n = 109

  

 Total-NPI scores

8.00 (2.00, 18.00)

14.00 (4.00, 21.50)

-2.486

0.013

 Delusions

114 (32.85%)

47 (43.12%)

3.827

0.050

 Hallucinations

260 (74.93%)

89 (81.65%)

2.088

0.148

 Agitation

86 (24.78%)

33 (30.28%)

1.297

0.255

 Depression

133 (38.33%)

51 (46.79%)

2.467

0.116

 Anxiety

117 (33.72)

47 (43.12%)

3.184

0.074

 Euphoria

20 (5.76%)

13 (11.93%)

4.693

0.030

 Apathy

129 (37.18%)

45 (41.28%)

0.593

0.441

 Disinhibition

32 (9.22%)

22 (20.18%)

9.547

0.002

 Irritability

107 (30.84%)

50 (45.87%)

8.306

0.004

 Aberrant motor behavior

94 (27.09%)

42 (38.53%)

5.189

0.023

 Night-time behavior disturbances

89 (25.65%)

25 (22.94%)

0.141

0.707

 Appetite and eating abnormalities

93 (43.87%)

48 (59.26%)

0.326

0.568

  1. Since all of the continuous variables did not follow a normal distribution, we described them as the median (interquartile range, IQR). And categorical variables were described as number of cases and proportions (n, %) in this table. Comparisons between the two groups were performed using chi-squared tests for categorical variables, and Mann–Whitney U-test for continuous variables
  2. CMBs, cerebral microbleeds; T2DM, type 2 diabetes mellitus; MTA, medial temporal lobe atrophy; RBD, rapid eye movement sleep behavior disorder; UPDRS-III, Unified Parkinson’s Disease Rating Scale-Part III; MMSE, the Mini-Mental State Examination; MoCA, the Montreal Cognitive Assessment; ADL, the Activity of Daily Living Scale; CDR, the clinical dementia rating; NPI, the Neuropsychiatric Inventory